Atara Biotherapeutics, Inc.

As of May 4, 2021, Atara Biotherapeutics, Inc. is considered risky and overvalued based on its financial metrics, despite a strong one-year return of 53.37%, due to poor long-term performance and unfavorable comparisons with peers.

As of May 4, 2021, Atara Biotherapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a P/E ratio of -9.69 and a year-to-date decline of 40.80%, compared to a 2.44% increase in the S&P 500.

As of June 3, 2025, Atara Biotherapeutics, Inc. shows a mildly bullish trend overall, supported by weekly MACD and KST indicators, despite some short-term bearishness indicated by daily moving averages.

As of March 2022, the management team of Atara Biotherapeutics, Inc. includes Chairman Ronald Renaud, CEO Dr. Pascal Touchon, Lead Independent Director Dr. Carol Gallagher, and Directors Dr. Maria Roncarolo, Dr. Roy Baynes, Mr. Eric Dobmeier, and Mr. Matthew Fust. They oversee the company's strategic direction and operations.

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for severe diseases. As of March 2025, it reported net sales of $98 million and a net profit of $38 million, with a market cap of $53.01 million.

As of Jun 18, Atara Biotherapeutics, Inc. has a market capitalization of 53.01 million, classifying it as a Micro Cap company, with net sales of 199.73 million and a net profit of -15.64 million over the last four quarters. The company has shareholder's funds of -97.28 million and total assets of 109.10 million as of Dec 24.